Picture of Ergomed logo

ERGO Ergomed News Story

0.000.00%
gb flag iconLast trade - 00:00
HealthcareSpeculativeMid CapHigh Flyer

REG - Ergomed plc - Total Voting Rights





 




RNS Number : 5093R
Ergomed plc
01 March 2019
 

PRESS RELEASE

   FOR IMMEDIATE RELEASE

 

 

Total Voting Rights

 

Guildford, UK - 1 March 2019: In accordance with the Financial Conduct Authority's Disclosure Guidance and Transparency Rules (DTRs), Ergomed plc (the "Company") announces the following information.

 

The Company's issued share capital as at 28 February 2019 consisted of 46,141,438 ordinary shares of 1p each, none of which were held in treasury.  Each ordinary share in the capital of the Company carries one voting right. 

 

The above figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company, under the DTRs.

 

- Ends -

 

Enquiries:

 

Ergomed plc

   Tel: +44 (0) 1483 402 975

Miroslav Reljanovic (Executive Chairman)

 

Stuart Jackson (Chief Financial Officer)

 

 

 

Numis Securities Limited

Tel: +44 (0) 20 7260 1000

Michael Meade / Freddie Barnfield (Nominated Adviser)

 

James Black (Joint Broker)

 

 

 

 

 

Consilium Strategic Communications - for UK enquiries

Tel: +44 (0) 20 3709 5700

Chris Gardner / Mary-Jane Elliott

ergomed@consilium-comms.com

Matthew Neal / Olivia Manser

 

 

 

MC Services - for Continental European enquiries

Tel: +49 211 5292 5222

Anne Hennecke

 

 

About Ergomed plc

Ergomed provides specialist services to the pharmaceutical industry spanning all phases of clinical development, post-approval pharmacovigilance and medical information. Ergomed's fast-growing, profitable services offering encompasses a complete suite of specialist pharmacovigilance solutions, integrated under the PrimeVigilance brand, in addition to a full range of high quality contract research and trial management services (CRO). Leveraging its CRO expertise, Ergomed also has a drug development portfolio of co-development partnerships and wholly-owned programmes. For further information, visit: http://ergomedplc.com


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
TVRTPMRTMBATBJL

Recent news on Ergomed

See all news